title: [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
abstract: For the breakthrough of the tumor escape mechanisms, immuno-chemo-combined therapy has been conducted. Tumor cell killing by anticancer drugs may be supported by their immuno- and pharmacologic effects. Chemotherapy is in fact able to up regulate tumor-associated antigen expression, and down regulate tumor cell resistance to the cytotoxic T lymphocytes. We conducted a phase II trials, administration of epitope peptides with FOLFOX to evaluate immunologic and clinical responses. Research into biomarkers that correlate with the clinical outcome of immunotherapy has behind vaccine development. Very few immunological or other markers exist that can be used in clinical trials for immunotherapy. We discuss with biomarkers specifically for the efficacy and monitoring of cancer vaccines.
authors.affiliation: Digestive Surgery and Surgical Oncology (Surgery II), Yamaguchi University Graduate School of Medicine.
authors.forename: Shoichi
authors.initials: S
authors.lastname: Hazama
authors.forename: Kazunari
authors.initials: K
authors.lastname: Maeda
authors.forename: Masaaki
authors.initials: M
authors.lastname: Oka
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D015415:Biomarkers / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D019496:Cancer Vaccines; D000939:Epitopes; D022223:Vaccines, Subunit